Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 01:40PM GMT
Release Date Price: R$19.8 (+0.81%)
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

I'd like to welcome Eli Lilly to the Cowen conference. Representing the company is Josh Smiley, who is the Chief Financial Officer. Let me note that next month marks the sixth year anniversary of the Cowen upgrade of Eli Lilly. And it was really an easy call because innovative, creative companies turn out to be good stocks in this industry, and Lilly has been a consistently good performer during that period. So Josh, thank you so much for spending this time with us.

I had the pleasure of having dinner last night with Josh with a small group of other people. And I think I follow the company pretty closely, and I listen to everything the company says, and I try to remember what the company says. And I guess I was most impressed with the conviction that you articulated for the outlook over the next 5 years. And again, I've heard it before, but I was just impressed with your confidence in your conviction, and I just wrote down a few things, which I'll just read off.

So revenue, top tier of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot